TY - JOUR
T1 - Barrett's esophagus in 2012
T2 - Updates in pathogenesis, treatment, and surveillance
AU - Chandra, Subhash
AU - Gorospe, Emmanuel C.
AU - Leggett, Cadman L.
AU - Wang, Kenneth K.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2013/5
Y1 - 2013/5
N2 - Barrett's esophagus (BE) is the only established precursor lesion in the development of esophageal adenocarcinoma (EAC) and it increases the risk of cancer by 11-fold. It is regarded as a complication of gastroesophageal reflux disease. There is an ever-increasing body of knowledge on the pathogenesis, diagnosis, treatment, and surveillance of BE and its associated dysplasia. In this review, we summarize the latest advances in BE research and clinical practice in the past 2 years. It is critical to understand the molecular underpinnings of this disorder to comprehend the clinical outcomes of the disease. For clinical gastroenterologists, there is also continuous growth of endoscopic approaches which is daunting, and further improvements in the detection and treatment of BE and early EAC are anticipated. In the future, we may see the increased role of biomarkers, both molecular and imaging, in both diagnostic and therapeutic strategies for BE.
AB - Barrett's esophagus (BE) is the only established precursor lesion in the development of esophageal adenocarcinoma (EAC) and it increases the risk of cancer by 11-fold. It is regarded as a complication of gastroesophageal reflux disease. There is an ever-increasing body of knowledge on the pathogenesis, diagnosis, treatment, and surveillance of BE and its associated dysplasia. In this review, we summarize the latest advances in BE research and clinical practice in the past 2 years. It is critical to understand the molecular underpinnings of this disorder to comprehend the clinical outcomes of the disease. For clinical gastroenterologists, there is also continuous growth of endoscopic approaches which is daunting, and further improvements in the detection and treatment of BE and early EAC are anticipated. In the future, we may see the increased role of biomarkers, both molecular and imaging, in both diagnostic and therapeutic strategies for BE.
KW - Acid reflux
KW - Barrett's esophagus
KW - Biomarkers
KW - Confocal laser endomicroscopy
KW - Cryotherapy
KW - Endoscopic mucosal resection
KW - Esophageal adenocarcinoma
KW - Narrow band imaging
KW - Obesity
KW - Optical coherence tomography
KW - Photodynamic therapy
KW - Radiofrequency ablation
UR - http://www.scopus.com/inward/record.url?scp=84876196825&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876196825&partnerID=8YFLogxK
U2 - 10.1007/s11894-013-0322-8
DO - 10.1007/s11894-013-0322-8
M3 - Article
C2 - 23605564
AN - SCOPUS:84876196825
VL - 15
JO - Current Gastroenterology Reports
JF - Current Gastroenterology Reports
SN - 1522-8037
IS - 5
M1 - 322
ER -